Alzheimer’s Disease Research Compendium

Miao-Kun Sun (Editor)
Blanchette Rockefeller Neurosciences Institute, Rockville, MD, USA

Series: Neurodegenerative Diseases – Laboratory and Clinical Research, Neuroscience Research Progress
BISAC: MED057000

Clear

$370.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Dementia is a brain disorder that seriously affects a person’s ability to carry out daily activities. The most common form of dementia among older people is Alzheimer’s Disease (AD), which involves the parts of the brain that control thought, memory, and language. Age is the most important known risk factor for AD. The number of people with the disease doubles every 5 years beyond age 65. AD is a slow disease, starting with mild memory problems and ending with severe brain damage. The course the disease takes and the speed at which changes occur vary from person to person. On average, AD patients live from 8 to 10 years after they are diagnosed, though the disease can last for as many as 20 years. Current research is aimed at understanding why AD occurs and who is at greatest risk of developing it, improving the accuracy of diagnosis and the ability to identify those at risk, discovering, developing, and testing new treatments, and discovering treatments for behavioral problems in patients with AD. This book presents the latest research in the field. (Imprint: Nova Biomedical )

Preface pp. i-xviii

1. SSAO and Aβ in Vascular Damage in the Temporal Cortex From Alzheimer and Alzheimer With Diabetes Patients
(Tony Valente, Montse Solé, Alejandro Gella, Nuria Durany and Mercedes Unzeta)pp. 1-10

2. Amyloid Precursor Protein in Central and Peripheral Cholinergic Synaptopathies (Virginia Borroni and Francisco J. Barrantes)pp. 11-30

3. In Vivo Analysis Using a Presenilin-1-Specific Inhibitor: Presenilin1-Containing -Secretase Complexes Mediate the Majority of CNS A Production in the Mouse
(Tomas Borgegård, Alexander Minidis, Anders Jureus, Jonas Malmborg, Susanne Rosqvist, Susanne Gruber, Helena Almqvist, Hongmei Yan, Anna Bogstedt, Fredrik Olsson, Jessie Dahlström, Colin Ray, Katja Närhi, David Malinowsky, Elin Hagström, Shaobo Jin, Åsa Malmberg, Urban Lendahl and Johan Lundkvist)pp. 31-48

4. Insight Into ‘Synaptopathy’ in Alzheimer’s Disease: From Lifestyle to PS1/N-Cadherin Interaction
(Akira Kuzuya, Ayae Kinoshita and Kengo Uemura)pp. 49-58

5. Interaction and Stimulation Through a Computer: A Program Specially Designed for Mild to Moderate Alzheimer's Patients
(M. de Sant’Anna, C. Vallet, D. Stefanucci, J. Rozenberg and
A.S. Rigaud)pp. 59-72

6. Novel Therapies for Alzheimer's Disease: Potentially Disease
Modifying Drugs
(Daniela Galimberti, Chiara Fenoglio and Elio Scarpini)pp. 73-96

7. Insights from Proteomics into Mild Cognitive Impairment, Likely the Earliest Stage of Alzheimer’s Disease
(Renã A. S. Robinson and D. Allan Butterfield)pp. 97-116

8. The Cholinergic Neuron in Alzheimer’s Disease
(Christian Humpel and Celine Ullrich)pp. 117-130

9. Retinal Neurodegeneration is an Early Event in the Pathogenesis of Diabetic Retinopathy: Therapeutic Implications
(Rafael Simó and Cristina Hernández)pp. 131-142

10. Category-Specific Semantics in Alzheimer’s Dementia and Normal Aging? (Keith R. Laws, Tim M. Gale, F. Javier Moreno-Martínez,
Rebecca L. Adlington, Karen Irvine and Sunil Sthanakiya)pp. 143-164

11. Category and Letter Fluency in Primary Progressive Aphasia, Semantic Dementia and Alzheimer’s Disease pp. 165-182
(Cecile A. Marczinski)

12. Down Syndrome and Alzheimer Disease: A “Multi-Hit” Hypothesis based on Multiple Contributing Factors Resulting in Pleotrophic Consequences
(David J. Bonda, Rudy J. Castellani, Hyoung-gon Lee, Massimo Tabaton, Gemma Casadesus, George Perry, Xiongwei Zhu and Mark A. Smith)pp. 183-194

13. Role of Glycogen Synthase Kinase-3B on TAU Phosphorylation in Alzheimer's Disease
(Rosa Resende, Catarina Resende Oliveira and Cláudia MF Pereira)pp. 195-208

14. Cognitive Rehabilitation in Middle-Aged Alzheimer Patients
(Elisabetta Farina and Fabiana Villanelli)pp. 209-230

15. Trafficking and Endocytosis of Alzheimer Amyloid Precursor Protein
(Ritva Tikkanen, Antje Banning and Melanie Meister)pp. 231-270

16. Endocytic Dysfunction and Alzheimer's Disease
(Nobuyuki Kimura)pp. 271-278

17. The Role of Alleles 4 and 2 of the APOE Gene and Cognitive Tests in the Early Conversion of Mild Cognitive Impairment to Alzheimer Dementia
(Ana Barabash, Alberto Marcos, Inés Ancin, Blanca M. Vazquez, Pedro Gil, Cristina Fernández, Juan José López-Ibor and José Antonio Cabranes)pp. 279-294

18. Changing Concepts of Alzheimer’s Disease: Roles of MRI
(Marie Cécile and Henry Feugeas)pp. 295-314

19. Mechanisms of Brain Aging Regulation by Insulin: Implications for Neurodegeneration in Alzheimer’s Disease and Other Disorders
(Artur F. Schuh, Jonas A. Saute, Carlos R. Rieder, Márcia Chaves and Matheus Roriz-Cruz)pp. 315-334

20. DYRK1A Kinase and Neuronal Cytoskeleton: A New Look at Pathogenesis of Alzheimer’s Disease Dementia from the Perspective of Down Syndrome
(Karol Dowjat) pp. 335-340

21. The Next Major Neuropsychological and Neuropsychiatrical Breakthrough: Alzheimer's Disease
(Heather Pedersen and F. Richard Ferraro)pp. 341-346

22. Animal Models of Alzheimer Disease for Translational Research: Current and Future Concepts
(Shuko Takeda, Naoyuki Sato, Hiromi Rakugi and Ryuichi Morishita)pp. 347-360

23. Unawareness of Deficits in Alzheimer's Disease Through a Biopsychosocial Perspective
(Martina Amanzio and Diana M.E. Torta)pp. 361-376

Index pp. 377-404

You have not viewed any product yet.


SHOW ALL OF MY RECENTLY VIEWED BOOKS